Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Rigel Pharmaceuticals (RIGL) announced the FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic ...

Rigel Pharmaceuticals on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to its proposed R289 treatment for myelodysplastic syndromes, a group of rare blood cancers ...

Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib. Read why RIGL stock is ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

U.S. stock markets witnessed an impressive rally in 2024 after an astonishing bull run in 2023. Following the 24.2% ascent in ...

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease ...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology.

Cantor Fitzgerald raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $25 from $15 and keeps a Neutral rating on the shares. Rigel announced initial data from the Phase 1b study of ...

Rigel Pharmaceuticals (RIGL) announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to R289 for the treatment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has ...